X

Drug Profile

Minocycline/rifampicin - Citius Pharmaceuticals Inc

Alternative Names: CITI 101; Mino-Wrap™

Latest Information Update: 26 May 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator M. D. Anderson Cancer Center
Developer Citius Pharmaceuticals Inc
Class Anti-infectives; Antibacterials; Rifamycins; Tetracyclines
Mechanism of Action DNA-directed RNA polymerase inhibitors; Protein 30S ribosomal subunit inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Infections

Most Recent Events

13 May 2021 Preclinical trials in Infections in USA (unspecified route)
16 Feb 2021 Citius Pharmaceuticals plans to file an IND by the end of 2021
16 Feb 2021 Citius Pharmaceuticals plans pre-clinical pharmacology and toxicology studies within the next few months

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com